EDUCATING PATIENTS ON ACS

 

KEY RISK FACTORS FOR ANOTHER CV EVENT IN POST-MI PATIENTS1

  • Patient age
  • Medical history
  • Comorbidities
  • Severity of an ACS event

AFTER AN ACS EVENT

PATIENTS’ THROMBOTIC CV RISK IS PERMANENTLY ELEVATED

 
Patients’ post thrombotic CV risk
Patients’ post thrombotic CV risk

RELATED LINKS:

Provide materials to help support the patient journey

 
 

PATIENT EDUCATION SHOULD ALSO FOCUS ON KEY RISK FACTORS FOR ANOTHER ACS EVENT, WHICH INCLUDE4-8:

  • Patient age
  • Medical history
  • Comorbidities
  • Severity of an ACS event

 

Patients’ NSTEMI risk is higher than STEMI.
Patients’ NSTEMI risk is higher than STEMI.

RELATED LINKS:

Provide materials to help support the patient journey

See data for the NSTEMI subgroup in the PLATO trial

QUESTIONS TO CONSIDER WHEN TALKING TO YOUR PATIENTS WHO RECENTLY EXPERIENCED AN MI

Do your patients understand their risk of having another heart attack?

Do your patients understand why you’ve chosen their treatment regimen, including their oral antiplatelet?

Are your patients aware of how to take their treatment regimen, including their oral antiplatelet?

Do they understand how long they may need to take medications, including their oral antiplatelet, and potential reasons for discontinuation?

Do they know that it’s important to stay on their treatments for as long as their doctor recommends?

Are they aware of what lifestyle modifications they need to make, such as diet, exercise, cardiac rehabilitation, and management of comorbidities?

Are your patients aware of the possible side effects of their medications, including their oral antiplatelet?

Do your patients understand the importance of talking to other physicians about the medications they are taking, including their oral antiplatelet?

RELATED LINKS:

Provide materials to help support the patient journey

Link your eligible patients to savings on their BRILINTA therapy
GET THE CARD
Efficacy data supports BRILINTA as a Standard of Care
SEE THE DATA
 

INDICATIONS

BRILINTA is indicated to reduce the rate of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. For at least the first 12 months following ACS, it is superior to clopidogrel.

BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.

DOSING

In the management of ACS, initiate BRILINTA treatment with a 180-mg loading dose. Administer 90 mg twice daily during the first year after an ACS event. After one year administer 60 mg twice daily. Use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg.

IMPORTANT SAFETY INFORMATION FOR BRILINTA® (ticagrelor) 60-MG AND 90-MG TABLETS

WARNING: (A) BLEEDING RISK, (B) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS

A. BLEEDING RISK

  • BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding
  • Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage
  • Do not start BRILINTA in patients undergoing urgent coronary artery bypass graft surgery
  • If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events

B. ASPIRIN DOSE AND BRILINTA EFFECTIVENESS

  • Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided

CONTRAINDICATIONS

  • BRILINTA is contraindicated in patients with a history of intracranial hemorrhage or active pathological bleeding such as peptic ulcer or intracranial hemorrhage. BRILINTA is also contraindicated in patients with hypersensitivity (eg, angioedema) to ticagrelor or any component of the product

WARNINGS AND PRECAUTIONS

  • Dyspnea was reported in about 14% of patients treated with BRILINTA, more frequently than in patients treated with control agents. Dyspnea resulting from BRILINTA is often self-limiting
  • Discontinuation of BRILINTA will increase the risk of MI, stroke, and death. When possible, interrupt therapy with BRILINTA for 5 days prior to surgery that has a major risk of bleeding. If BRILINTA must be temporarily discontinued, restart as soon as possible
  • Ticagrelor can cause ventricular pauses. Bradyarrhythmias including AV block have been reported in the post-marketing setting. PLATO and PEGASUS excluded patients at increased risk of bradyarrhythmias not protected by a pacemaker, and they may be at increased risk of developing bradyarrhythmias with ticagrelor
  • Avoid use of BRILINTA in patients with severe hepatic impairment. Severe hepatic impairment is likely to increase serum concentration of ticagrelor and there are no studies of BRILINTA in these patients

ADVERSE REACTIONS

  • The most common adverse reactions associated with the use of BRILINTA included bleeding and dyspnea: In PLATO, for BRILINTA vs clopidogrel, non-CABG PLATO-defined major bleeding (3.9% vs 3.3%) and dyspnea (14% vs 8%); in PEGASUS, BRILINTA vs aspirin alone, TIMI Total Major bleeding (1.7% vs 0.8%) and dyspnea (14% vs 6%)

DRUG INTERACTIONS

  • Avoid use with strong CYP3A inhibitors and strong CYP3A inducers. BRILINTA is metabolized by CYP3A4/5. Strong inhibitors substantially increase ticagrelor exposure and so increase the risk of adverse events. Strong inducers substantially reduce ticagrelor exposure and so decrease the efficacy of ticagrelor
  • As with other oral P2Y12 inhibitors, co-administration of opioid agonists delay and reduce the absorption of ticagrelor. Consider use of a parenteral anti-platelet in ACS patients requiring co-administration
  • Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse events
  • Monitor digoxin levels with initiation of, or change in, BRILINTA therapy

SPECIAL POPULATIONS

  • Lactation: Breastfeeding not recommended

Please read full Prescribing Information, including Boxed WARNINGS, and Medication Guide.